Cognitive impairment in patients with cerebrovascular disease: A white paper from the ESO Dementia Committee by Verdelho, Ana et al.
Review article
Cognitive impairment in patients with
cerebrovascular disease: A white paper
from the links between stroke ESO
Dementia Committee
Ana Verdelho1 , Joanna Wardlaw2 , Aleksandra Pavlovic3,
Leonardo Pantoni4 , Olivier Godefroy5, Marco Duering6,7,
Andreas Charidimou8,9, Hugues Chabriat10 and
Geert Jan Biessels11
Abstract
Purpose: Many daily-life clinical decisions in patients with cerebrovascular disease and cognitive impairment are com-
plex. Evidence-based information sustaining these decisions is frequently lacking. The aim of this paper is to propose a
practical clinical approach to cognitive impairments in patients with known cerebrovascular disease.
Methods: The document was produced by the Dementia Committee of the European Stroke Organisation (ESO),
based on evidence from the literature where available and on the clinical experience of the Committee members. This
paper was endorsed by the ESO.
Findings: Many patients with stroke or other cerebrovascular disease have cognitive impairment, but this is often not
recognized. With improvement in acute stroke care, and with the ageing of populations, it is expected that more stroke
survivors and more patients with cerebrovascular disease will need adequate management of cognitive impairment of
vascular etiology. This document was conceived for the use of strokologists and for those clinicians involved in cerebro-
vascular disease, with specific and practical hints concerning diagnostic tools, cognitive impairment management and
decision on some therapeutic options.
Discussion and conclusions: It is essential to consider a possible cognitive deterioration in every patient who experi-
ences a stroke. Neuropsychological evaluation should be adapted to the clinical status. Brain imaging is the most
informative biomarker concerning prognosis. Treatment should always include adequate secondary prevention.
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Vascular risk factors are recognized as one of the main
determinants of cognitive impairment associated with
ageing.1,2 Cognitive impairment (CI) due to cerebro-
vascular disease (CVD) can exist after stroke or in
the context of chronic CVD without previous stroke,
representing a leading concern of patients and care-
givers.3 Although acute stroke care has evolved sub-
stantially over the last decades, post-stroke cognitive
impairment (PSCI) remains frequently underdiagnosed
as it may be overlooked in the presence of other dis-
tressing signs (for instance motor or visual symptoms).
Consequently, cognitive impact of acute stroke is often
underestimated. Moreover, subtle and progressive
decline might also be caused by vascular lesions (e.g.
either lesions related to small vessel disease (SVD),
repetitive minor injuries, or vascular consequences of
systemic failure as for instance cardiac insufficiency).
Stroke clinicians are well trained in the identification of
stroke, but do not always recognize the myriad of cog-
nitive and behavioural symptoms that accompany
stroke in the acute and chronic phases.
Methods
This paper is a result of an effort of the ESO Dementia
Committee (2018-2020), under the approval of the ESO
Executive Committee, aiming to produce some practi-
cal clinical suggestions on the identification, diagnosis
and management of CI for clinicians involved in the
management of patients with stroke. Its use is not only
for strokologists, but also for others professionals
involved in the management of patients with CI due
to vascular pathology. Several comprehensive and
updated reviews are available on the topic, acknowl-
edged throughout this paper, and we did not aim to do
an exhaustive or systematic review or to cover all cur-
rent evidence. We tried to incorporate differences of
approach and access to ancillary investigations, keep-
ing in mind the standard usual best practice.
Concerning CI in the context of CVD, different ter-
minologies exist,4–6 and consensus is missing, although
those terms refer broadly to the same or quite similar
entities. In order to be practical, for the purpose of this
paper, we will use vascular dementia (VD),4 major vas-
cular cognitive impairment/disorder5 and the more
recent major vascular neurocognitive disorder
(NCD)6 interchangeably, and where less severely
affected, we use mild cognitive impairment/disorder
or mild NCD.5,6 Post-stroke dementia (PSD) or post-
stroke cognitive impairment (PSCI) will be used when
it refers to stroke patients, irrespectively of the time
elapsed since stroke.
Findings
How to recognize cognitive complaints/impairment
Cognitive impairment due to CVD can occur in differ-
ent settings: after a stroke (PSCI), in the acute stage, in
the recovery stage (while other stroke symptoms
improve), or delayed until months/years after stroke.
When CI due to CVD follows repetitive or chronic
vascular lesions, identification of those symptoms
may be difficult as they might be quite subtle and mis-
leading. Characteristically, and apart from focal cogni-
tive symptoms due to stroke itself (such as aphasia and
hemineglect), the initial symptoms may be hard to iden-
tify. These symptoms might include reduced initiative
for usual tasks, slowness, and higher latency to start an
answer/action. Patients may accept undertaking
actions if externally motivated and initiated and more
time may be needed. Because attention is impaired,
patients are easily distracted even by irrelevant stimuli.
Multi-tasking can be difficult, not only due to attention
shifting difficulties, but also to difficulty in alternating
between different tasks and patients may have difficul-
ties in making decisions. Sometimes, behaviour is pre-
dominantly affected and proxies/families acknowledge
some “personality” changes. Behaviour changes can
co-exist or even be the only initial manifestation, such
as more inflexible behaviour, with reduced tolerance to
changes of routine activities and repetition of the same
mistakes (as patients may not be able to correct them-
selves). Control of inhibition may be disturbed, loss of
control of emotional expression, as well as socially
inappropriate manifestations (even sexually inappro-
priate behaviour), although these latter are usually
less frequent and occur in more advanced stages.
Patients may be labelled as “depressed” although usu-
ally do not complain of sadness, and other key aspects
of depression are not present. As a result of the symp-
toms above, patients reduce their level of social inter-
action, quit usual hobbies and sometimes relatives/
caregivers takeover tasks intuitively. The keystone for
considering the above symptoms as a manifestation of
CVD is that they represent a change from a previous
way of functioning, implicate an adaptation in daily-
life, and finally, CVD is the presumed etiology.
Evolution might be stepwise, progressive, or fluctuant.
If only the patient is interviewed, it is possible to miss
the picture. Interview of a proxy(ies) may be necessary,
but beware of the patient who always looks to the part-
ner to answer and the obliging partner who provides all
the responses. Separate interview of the informant/rel-
atives should be considered whenever interview of both
patient and relative becomes a sensitive point, as rela-
tives/caregivers might be uncomfortable giving some
information or describing some details in the presence
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of the patient. This separate interview should, never-
theless, follow usual good practice approaches.
Criteria for CI and for CI due to CVD
Several sets of criteria for CI due to CVD have been
proposed,4,5 most of them requiring to demonstrate the
presence of CI, the presence of cerebral vascular lesions
and a relationship between them. The VASCOG crite-
ria5 have the advantage to define criteria for both mild
and major CI (based on the DSM-V)6 and for both
patients with stroke and those without stroke. This is
especially important considering studies showing that a
large proportion of patients with CI related to a cere-
brovascular lesion did not have a clinically-evident
stroke.7
The criterion of CI is operationalized in the diagnos-
tic criteria of CI due to CVD,4,5 although this opera-
tionalization still lacks consensus. Diagnosis of mild CI
frequently uses the 1.5 standard deviation threshold on
cognitive testing following criteria of Winblad et al.8
two thresholds have been proposed in the DSM-V (1
and 2 standard deviations for mild CI and major CI,
respectively).6 In addition, some teams and studies
applied these thresholds to each performance score or
to each domain summary scores. Moreover, different
results can be due to the chosen operationalized crite-
ria9 since normative data depend on selection of the
controls (volunteers, community or not community,
with or without brain imaging), which can, per se,
limit interpretation of findings. A strict and explicit
harmonization is needed as the use of different proce-
dures deeply influences the interpretation (at least in
patients with mild impairment) and the false positive
rate.10,11 The use of a global cognitive score summariz-
ing all domains and the fifth percentile threshold has
been shown to improve sensitivity while controlling for
specificity [i.e. false positive rate].10 Whatever the
chosen procedure, it is essential to ensure that it pro-
vides an optimal sensitivity and controls specificity ade-
quately. In addition, the selection (volunteers vs
general population), demographic characteristics (rep-
resentation of older and low education subjects) and
size sample of normative population influence the
determination of cognitive test cutoff scores.
The characteristics of vascular lesions in the brain
are detailed in the subsection ‘Predictors of CI and
dementia’. The relationship between CI and cerebro-
vascular lesions is typically operationalized by its tem-
poral course (i.e., onset within 3 months of diagnosed
stroke, abrupt onset, or stepwise progression).4,5
However, abrupt onset is rare in the absence of a
stroke, and stepwise progression is infrequent owing
to better prevention of stroke recurrence. This excludes
patients with non-acute CI due to vascular lesion
without clinical stroke, a situation which is especially
encountered in small vessel disease (SVD).
Purposefully the VASCOG criteria5 included this situ-
ation and consider the diagnosis of CI due to CVD
when deficits in executive functions and/or action
speed are prominent and associated with at least one
out of three features (gait disturbances, urinary control
disorders or mood changes).
How to evaluate the neuropsychological status in
stroke patients
Regarding stroke patients, we will focus on the post-
acute phase, i.e., 3 to 6 months post-stroke. Cognitive
assessment at the acute stroke onset should be per-
formed as part of the neurological examination and
contributes to the diagnosis of the acute condition in
the emergency room; in the stroke unit it usually con-
sists of clinical assessment and screening tests with,
when needed, language or hemineglect tests to
manage early rehabilitation.12 More detailed informa-
tion is already published.12 Although most post-stroke
assessments are now performed within 3-6 months,
timing of neuropsychological assessment may influence
the profile of CI: marked improvement in speed and
attention, frontal executive functions, perceptual and
nominal skills can occur over time, compared to
stable findings in verbal and visual memory.13,14
We propose that the initial full neuropsychological
evaluation should only be conducted after some stabi-
lization was achieved (possibly as late as 6 months after
a severe stroke), unless specific cognitive training could
be advised earlier (for instance cognitive intervention
for neglect). We do not advise to test and re-test repeat-
edly, unless specific questions arise (search for associ-
ated degenerative disease, driven ability or other legal
reason, or working difficulties and need for retirement
evaluation, for instance). In case re-test is needed for
clinical clarification, an ideal interval of 12 months
should be considered to avoid learning bias between
evaluations.
PSCI is observed in about 50% of stroke survivors,
two thirds of them corresponding to mild CI, and one
third to major CI according to present CI criteria (see
previous section).11,15,16 PSCI has a marked effect on
functional prognosis, risk of institutionalization15,17,18
and risk of recurrence of a major vascular event.19,20
Optimal diagnosis of PSCI should be based on com-
prehensive cognitive assessment in patients at risk of
CI. Although this is always a clinical indication, and
should, in the end, based on the individual level, some
cues can be given: this objective can be achieved using a
recently explored strategy based on risk factors of PSCI
(Table 1 provided in supplementary material, and
“Predictors” section).21 Several factors have been
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found to be associated with PSCI, major CI, in partic-
ular.10,16,22 A recent study has identified a minimal set
of factors for selecting patients at risk of full-spectrum
PSCI.21 The Rankin score represents an important step
provided it is graded with a reliable informant, using a
structured interview (including difficulties in instru-
mental activities of daily living).23 Except in specific
situations (e.g. return to a complex occupation), a com-
prehensive assessment might be considered to be futile
in patients having regained all pre-stroke activities
without any concerns (i.e., Rankin score¼0), and in
bedridden patients (i.e., Rankin score¼5). In the
same vein, comprehensive assessment is usually unnec-
essary for diagnosis in patients with substantial impair-
ment on screening tests.
The administration of a comprehensive neuropsy-
chological battery is the gold standard for the diagnosis
of CI but may be complex to perform and not feasible
in all stroke survivors and requires suitable quiet and
uninterrupted settings. Hence, the first line of cognitive
assessment usually relies on clinical examination and
screening tests such as Informant Questionnaire on
Cognitive Decline in the Elderly (mainly used to iden-
tify pre-stroke CI),24 MiniMental Status Examination
(MMSE)25 and Montreal Cognitive Assessment
(MoCA).26 These instruments are a first step and
may identify different severities of CI. We must
acknowledge that MMSE and MoCA do not have
interchangeable results. MoCA tests included more
nonverbal and non-memory items (namely visuospa-
tial/executive functions and attention) compared to
MMSE. A recent systematic review indicated good to
excellent accuracy, good internal consistency and good
reliability of MoCA in differentiating between both
mild CI and major CI patients from controls.27
Nevertheless, despite the mildly higher sensitivity of
MoCA as compared to MMSE,27 a low specificity28,29
still limits its use and both tests have only moderate to
good sensitivity for the diagnosis of PSCI.28–31 Thus,
both tests underestimate the impairment in a significant
proportion of affected patients, i.e. they miss about one
fifth of cognitively impaired patients, a proportion
which increases in mild PSCI. In addition, their specif-
icity is also lower than 100%,28,30,32 indicating that
mildly decreased scores might be observed in subjects
with normal comprehensive assessment. Score interpre-
tation needs to take into account the first language,
education level (for both tests) and age (for MoCA)
28,33; their scores might also be influenced by sensory-
motor deficit, deficits in language and perception
(hemi-neglect). Hence, it important to highlight that
screening tests scores need always to be integrated in
the clinical context and in the whole condition of the
patient, in order not to over value results of the screen-
ing tests.
Assessment of cognitive abilities is difficult in
patients with severe aphasia. In such cases diagnosis
of PSCI is usually made on the basis of an aphasia
battery and screening test. Further assessment might
be necessary to determine the cognitive profile (i.e.
associated memory disturbances, executive dysfunction
and action slowing). When comprehension abilities
allow the use of cognitive tests, further cognitive assess-
ment is usually based in non-verbal tests including
visual recognition tests (such as the Doors test, for
more details Table 2 in supplementary material), rea-
soning on visual material (such as Progressive
Matrices), visual-motor tests assessing attention and
processing speed (such as cancellation test, digit
symbol modalities subtest).
Which tests should be used in patients with
suspected CI due to CVD?
Considering the profile of vascular CI, a comprehen-
sive test/battery should assess attention, action speed
(also called psychomotor speed or processing speed),
cognitive and behavioural executive functions, episodic
Table 1. Diagnostic evaluation of patients with CI-CVD.
Step Aim of investigation
Risk factor assessment Stroke subtype
 Increased risk associated with haemorrhagic (comparing to ischemic strokes)
 Increased risk in cardioembolic etiology and large artery atherosclerosis
Clinical assessment Detection of CI and other manifestations (depression, apathy).
Functional status assessment
Brain imaging (MRI, if
contraindications: CT)
MRI preferred mode of examination
Differential diagnosis to other conditions causing CI.




Differential diagnosis to other conditions
CI – cognitive impairment; CVD – cerebrovascular disease; CSF - cerebrospinal fluid; MRI- Magnetic resonance imaging; CT- computerized tomography.
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memory, language, and visuo-constructive abilities as
well as depressive symptoms. When needed, this first
line of tests should be followed by optional tests assess-
ing aphasia, hemi-neglect, agnosia, etc. Cognitive
testing should anyway be adapted for the age and
sociocultural context, beyond specific stroke deficits.
The battery of tests is now standardized owing to the
Harmonization Standards protocol battery.34 This bat-
tery has been adapted into multiple languages and cul-
tures and interestingly it provides similar cognitive
profiles across countries, which sustains evidence for
the robustness and generalizability of the included
tests (detailed tests and references provided in Table 2
of supplemental material). Other studies have used neu-
ropsychological assessment, albeit different, that per-
mitted pooled analysis, including the main cognitive
domains identified by harmonization standards
protocol.35
Difficulties in activities of daily living (ADL) should
be assessed using scales that can distinguish those dif-
ficulties due to CI (as needed for a diagnosis of major
CI) from those due to sensory-motor deficit and less
frequently, to psychiatric disorders,4,5 as physical
impairment can be a confounder for diagnosis.10 As
this distinction (critical for the diagnosis of major CI)
may be challenging, some studies have used an adap-
tation of instrumental activities of daily living assess-
ment, with additional questions and examination that
identify the mechanism (sensory-motor, cognitive or
psychiatric depressive) accounting for the decline of
each activity.10 This poorly investigated area still
requires additional validation studies.
Predictors of CI
Several factors have been identified as predictive of
future mild or major CI in patients with CVD disease.
These factors can be informative for clinicians regard-
ing counselling of patients and relatives as well as selec-
tion of patients for more intensive follow-up and for
clinical trials.
Neuroimaging predictors of cognitive impairment in small
vessel disease. In patients with cerebral SVD (but not
necessarily with history of stroke), clinical status and
brain magnetic resonance imaging (MRI) aid in
predicting cognitive deterioration. While age and initial
clinical status (cognitive and functional assessments)
already predict future cognitive decline and incident
dementia to a large extent, brain MRI has added
value.36 Although volumetric measures, such as total
brain volume, white matter volume and hippocampal
volume, emerged as the most consistent imaging pre-
dictors,37,38 their practical use in non-specialized clini-
cal settings is scarce. Baseline white matter
hyperintensities (WMH) and lacunes (cavitated lesions)
have also been identified as independent predictors.37,39
More novel markers, such as diffusion (tensor) imaging
and structural network analysis, show potential,40,41
but still need further development and simplification
to be applicable in clinical routine care.
Neuroimaging predictors of post-stroke cognitive impairment.
Specific MRI markers as post-ischemic event predic-
tors have been summarized in a recent review.42 The
most consistent neuroimaging predictors of PSCI, in
addition to clinical predictors, were global and medial
temporal lobe atrophy.42,43 These data suggest that it
might be beneficial to use brain imaging (computerized
tomography - CT- or MRI) to identify stroke patients
with these atrophy patterns. Volume and location of
the infarct (including lacunes) and strategically-
located infarcts were also found to be major predic-
tors.43 Interestingly, data from the large STRIDE
study suggests that imaging predictors for PSCI may
differ depending on the time point of CI symptom
onset.44 While early PSCI showed the strongest associ-
ation with infarct features (mostly size and location),
delayed PSCI was strongly associated with (pre-exist-
ing) SVD on MRI,45 although these findings await rep-
lication in other studies. PSCI risk may differ according
to stroke subtype, with an increased risk of CI for
cardioembolic etiology and large artery atherosclero-
sis,46,47 while others reported no differences after
adjustment for other factors such as stroke severity
and premorbid status,48 or noted a significant progres-
sive trend of CI among patients with small vessel dis-
ease and lacunes up to 5 years after stroke47 (Table 1).
Pre-stroke brain pathology may contribute to cog-
nitive decline after stroke by increasing the susceptibil-
ity to CI. Because of their high prevalence in the
elderly, SVD and neurodegenerative pathology, in
Table 2. MRI sequences in CI due to CVD should include:59,80
Sequence Provides information on:
T1-weighted Brain morphology, focal or diffuse atrophy
T2-weighted or fluid-attenuated inversion recovery (FLAIR) White-matter hyperintensities, old vascular lesions
Diffusion-weighted imaging (DWI) Number, size and location of most recent ischemic lesions
Susceptibility-weighted imaging (SWI)/GRE-T2* Microbleeds, cortical superficial siderosis
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particular of the Alzheimer‘s disease (AD) type, are the
most obvious candidate predictors. An association
between pre-existing AD pathology detected by amy-
loid positron emission tomography (PET) and PSD
early after stroke has indeed been shown.49 However,
several studies do not support a prominent role of amy-
loid pathology in delayed PSCI50 or PSD,45,51 i.e., CI
occurring months to years after stroke.
MRI markers of SVD, such as WMH, lacunes, and
cerebral microbleeds should be assessed since these all
increase the risk of PSCI.52 A large comprehensive sys-
tematic review and meta-analysis clearly demonstrates
a strong association between increasing severity of
WMH (on MRI or CT) and several adverse outcomes
including subsequent dementia.52 Nevertheless, this
association becomes less strong with aging, when
degenerative pathology (AD type) probably superim-
posed on the impact of WMH.53 However, many stud-
ies did not account for factors such as premorbid
cognitive ability or resilience/reserve (discussed
below), which may partly account for the apparent
‘looseness’ of the association between WMH burden
and cognition.54 Given these results, the effect of
some other predictors of delayed PSCI, such as diabe-
tes, might at least in part be mediated by cerebral SVD,
and is potentially modifiable through better risk factor
control. The fact that delayed CI occurs months to
years after the initial stroke might open a time
window for therapeutic interventions, again emphasiz-
ing the importance of risk factor treatment after the
acute event.
From a practical point of view, infarct volume and
location, in combination with WMH, microbleeds and
atrophy (globally and medial temporal lobe), may be
the most important neuroimaging predictors of PSCI,51
providing added value on top of clinical variables.
Finally, it should be mentioned that predictors of
minor and major CI after ischemic stroke and after
intracerebral haemorrhage appear to be largely simi-
lar,22 with haemorrhagic stroke associated with an
increased risk of PSCI compared with ischemic
stroke.48,55
Clinical predictors. Predictors are of particular interest in
the context of PSCI, to identify patients at high-risk for
CI promptly identified after the acute event. Multiple
studies on PSCI identified predictors related to the con-
cept of brain resilience or reserve.44 This concept
addresses the phenomenon that the same level of
brain pathology leads to different levels of CI depend-
ing on the premorbid condition of the brain and pre-
sumably its ability to actively compensate for the
damage.56 Or. in other words, lower resilience leads
to a greater susceptibility for PSCI. Predictive factors
attributable to the concept of resilience or reserve are
level of education, early-life intelligence (also reflected
in type of job), leisure activities, as well as employment
and relationship status pre-stroke.10,57–60
The Oxford Vascular Study22 is at present the larg-
est prospective incidence study for PSD. Stroke severity
as measured by the National Health Institutes Stroke
Scale (NIHSS)61 score was one of the strongest predic-
tors of PSD. Other factors were age, previous stroke,
recurrent stroke, dysphasia, baseline cognition, low
education, pre-morbid dependency, leukoaraiosis - on
brain imaging-, and diabetes. The latter is of particular
interest for clinicians, since it was the only vascular risk
factor associated with PSD. This suggests that intensi-
fied risk factor management post-stroke might be most
effective in the case of diabetes, or reflect that hyper-
tension and hyperlipidaemia are already now well man-
aged. Recent data from the same study found that
APOE e4 homozygosity was associated with PSD, rein-
forcing the conviction of the influence of a previous
neurodegenerative pathology.62
Still concerning stroke survivors, a combined cogni-
tive risk score based on four easily documented factors
(severity of neurological deficit, presence of multiple
strokes, multiple deep WMH corresponding to
Fazekas score 2 and a mild decrease of MMSE
score, i.e., adjusted MMSE score from 21 to 27) pro-
vided a very good screening strategy21 but remains to
be tested independently and more widely in other
cohorts before adoption into practice.
A last word considering age. Although age is an
important predictor, PSCI, both acute and delayed, is
not infrequent in young stroke survivors, and consid-
ering relative risk (although not absolute risk), the
dementia risk is greater in younger populations.16,22
Inspite of that, predictors of post-stroke cognitive
status in this subpopulation are largely
understudied.63,64
Complementary investigations not to be missed
The large clinical and neuroimaging heterogeneity of
CI due to CVD explains the difficulty of developing a
standardized medical evaluation in the clinical setting
for all types of CI due to CVD.65,66
It should go without saying that all patients who are
seen in a CVD clinic have a comprehensive evidence-
based vascular risk factors assessment67,68 and a work-
up for determining the stroke subtype and potential
underlying mechanism.69–71 The underlying source of
vascular brain damage should be pursued in all CI due
to CVD patients72 in order to prevent subsequent/
recurrent strokes.
Clinical assessment of patients with CI due to CVD
should include the analysis of typical cognitive changes
(described above) but also the recognition of non-
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cognitive manifestations of CVD such as depression,
apathy, motor disability, gait difficulties, balance prob-
lems, sensorimotor deficit(s), sphincter control dys-
function, parkinsonism, pseudobulbar palsy and all
their possible functional consequences in daily life
(Table 1).
While functional outcome in patients surviving
acute stroke is well-established, comprising measures
of disability (modified Rankin scale score)73 and func-
tional independence (Barthel Index),74 other aspects of
activities and functional disturbances in daily living are
multifaceted, nuanced, difficult to delineate and not
well assessed using specific tools.65,66,75–77 Cognitive
impairment and executive dysfunction, in particular,
as well as depression and apathy, may all have a sig-
nificant impact on patients’ functional abilities and
independence.78 One practical way to assess this
impact is using the interview, with a relative/caregiver.
The interview should include aspects mentioned before
in “how to recognize cognitive impairment/
complaints” such as abandonment of leisure activities,
change of habits.
Laboratory analysis in CI due to CVD
No specific laboratory analysis or biomarker in the
blood or cerebrospinal fluid (CSF) is available yet for
determining the exact vascular injury responsible for CI
due to CVD.67 However, blood laboratory tests can
help identify and monitor vascular risk factors.
In patients with SVD, CSF studies may help in dif-
ferential diagnosis of inflammatory myelin disorders or
to exclude vasculitis.79 CSF protein examination can
provide evidence of blood-brain barrier disruption
(increased albuminCSF to albuminblood ratio).
60,79
Analysis of CSF markers of cortical neuronal degen-
eration and amyloid pathology may help in detecting
mixed etiologies (namely with AD -reduced amyloid
b1-42 - also detected in amyloid angiopathy - associat-
ed with increased phosphorylated-tau).79 Other multi-
ple markers are so far of limited value in clinical
practice,80–83 such as serum and CSF inflammatory
markers, markers of extracellular matrix breakdown
(matrix metalloproteinases) or of neuroaxonal
damage (serum neurofilament light chain), markers of
hypercoagulable state, oxidative stress as well as other
metabolic markers (e.g., homocysteine).
Neuroimaging in CI due to CVD
Neuroimaging will have been performed in most
patients in the acute setting to assess the stroke sub-
type, and to plan the secondary prevention strategy at
individual level (Table 3 in supplementary materi-
al).66,72,84,85 This imaging can also support the
evaluation of the likely cause of CI. In this context,
the best imaging tool is brain MRI, which can be con-
sidered as the gold standard for diagnosis of CI due to
CVD,65 although CT scanning is the most widely avail-
able method and provides relevant information on
stroke type and pre-stroke brain changes including leu-
koaraiosis and atrophy. MRI examination should
include sequences shown in Table 2.
MRI can also show suggestive patterns of lesions in
favor of specific underlying disorders; Cerebral
Autosomal Dominant Arteriopathy with Subcortical
Infarcts and Leukoencephalopathy (CADASIL) is
often associated with temporal pole T2 hyperinten-
sities; cerebral amyloid angiopathy (CAA) often leads
to lobar macro- and microbleeds and cortical superfi-
cial siderosis.86,87 Diffusion tensor imaging that can
probe the microstructure of white matter (even in oth-
erwise normal appearing brain tissue), as well various
refined MRI modalities (high-resolution MRI systems,
proton NMR spectroscopy and dynamic contrast-
enhanced MRI) can provide information about the
tissue status but are not used in daily clinical prac-
tice.40,79,88 Neuroimaging acquisition, interpretation
and reporting of cerebral SVD are now better stan-
dardized, and the Standards for ReportIng Vascular
changes in nEuroimaging (STRIVE) criteria have
been proposed to better define MRI lesions.89 In
patients with MRI contraindications, CT scans can
depict atrophy, intracranial haemorrhage, acute and
old infarcts, and, to a lesser degree, lacunes and exten-
sive WMH.67 The use of fluorodeoxyglucose -PET is
not helpful for differentiating AD from patients with
vascular pathology.90 In a recent meta-analysis, PET
amyloid positivity (a classical feature in presence of
CAA or AD) has been reported in elderly APOE e4
carriers meeting the criteria of VD, and a further
increase may be observed in PSD subjects,50,67,91 sug-
gesting a contribution from AD pathology, and a
mixed etiology in older patients with PSD.
Integration of diagnostic information and diagnostic
labels
Complementary investigations may be needed for the
differential diagnosis of MRI-identified lesions (e.g.
vascular versus demyelinating lesions in younger
patients, or differential diagnosis of white matter
lesions at different ages)92,93 or for identifying associ-
ated disorders, particularly neurodegenerative condi-
tions that develop with aging.79 In hereditary forms
of CI due to CVD, the patient should be referred to a
comprehensive center enabling diagnosis of genetic dis-
eases which can help to reduce unnecessary diagnostic
procedures and implement treatment strategies.
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Treatment to improve cognition in patients with CI
due to CVD
Currently, there is no specifically approved treatment
for CI due to CVD. A systematic review of cholines-
terase inhibitors (donepezil, rivastigmine, galantamine)
and N-methyl-d-aspartate receptor antagonists (mem-
antine) suggested that these drugs improved cognition
in CI due to CVD, but did not improve behaviour or
functional status.94,95 It should be noted, however, that
due to the limitations of inclusion and diagnostic crite-
ria, the vascular origin of cognitive impairment could
not be determined in all participants in any of the trials.
More dropouts and adverse events (anorexia, nausea,
vomiting, diarrhea, and insomnia) occurred with cho-
linesterase inhibitors compared with memantine. In
CADASIL, a pure form of VD,96 the use of donepezil
was also found to improve some executive performan-
ces but without improving activities of daily living.97
Hence, these drugs are not recommended when CI or
dementia is of purely vascular origin. However, they
can be considered at individual level when the vascular
component of dementia is associated with a degenera-
tive disease such as AD, which might be the case in
many patients seen in daily practice, particularly
older patients.
No significant effect was detected on CI due to CVD
using nimodipine, piracetam, huperzine A, cytidine di-
phosphocholine and vinpocetine. Other molecules have
shown a limited benefit in patients with CI due to CVD
(dl-3-n-butylphthalide, gingko biloba extract, cerebro-
lysin, actogevin).72,98 The results were obtained in small
samples or only in subgroups of individuals and were
not replicated at large scale. Therefore, we see no evi-
dence to recommend these drugs in patients with CI
due to CVD.
In conclusion, the use of cholinesterase inhibitors
and memantine might be considered in patients with
CI due to CVD only very cautiously and on a case-
by-case basis where AD is thought to contribute,
depending on the authorization available in the coun-
try, the individual tolerance of the treatment and the
perceived benefit during follow-up.
Prevention in patients with CI due to CVD
In patients with CI due to CVD or at risk of developing
CI of vascular origin, it is obviously crucial to prevent
the occurrence of any new stroke event or incident cere-
brovascular lesion. The assessment of the underlying
CVD and all measures to reduce its progression
should be undertaken in all patients.
Control of vascular risk factors and lifestyle changes
have limited effects at cognitive level, with exception of
hypertension (with suggestions of some benefit from
randomized studies),99 but globally, multi-domain
interventions, including non-pharmacologic and life-
style modifications showed no consistent benefit in cog-
nition in stroke survivors.100–103
Patients with CI due to CVD should be treated as
usually recommended after the occurrence of an acute
ischemic or haemorrhagic stroke.104 In patients with a
past history of ischemic stroke, there is accumulating
evidence suggesting that the number of microbleeds on
MRI imaging should no longer be considered as a
contra-indication to antithrombotic drugs.105 Recent
data support that in the vast majority of cases, the
absolute risk of ischemic events largely exceeds that
of haemorrhages. Only the presence of lobar haemor-
rhage in probable CAA, anticoagulant should be thor-
oughly discussed dependent on the level of risk of
ischemic events.
Particular attention must be paid to patients with CI
due to CVD when cognitive deficits are severe, to assess
the risk related to therapeutic compliance, including
errors or misunderstanding regarding the use of antith-
rombotic treatments.106 In some individuals, a caregiv-
er may be needed to control the treatment
administration. When in doubt, treatments that
expose a high risk of complications might be avoided.
Reperfusion therapies in presence of CI
There is no study examining specifically the potential
of thrombolysis or thrombectomy to treat acute ische-
mic stroke in patients with CI due to CVD. However,
the risk of death and haemorrhage is not increased in
persons suffering from dementia107 and there is some
evidence that persons with dementia may benefit as do
other acute stroke patients from intravenous rt-PA.108
Therefore, thrombolysis or thrombectomy should be
considered in all acute stroke patients including those
with CI due to CVD. However, the premorbid level of
function, quality of life, social support and life expec-
tancy should be weighted whenever possible before
deciding to treat as they can be major determining fac-
tors in outcome.107
Hence, the use of cerebral reperfusion therapies
should not be ruled out in patients with CI.
Individual decisions of not to treat maybe taken,
namely in situations where autonomy is already severe-
ly affected and when large lesions cannot be significant-
ly reduced by the treatment.
Discussion and conclusion
Additional investigations are needed to improve the
management of cognitive disorders due to cerebrovas-
cular pathology. The development of innovative pre-
ventive therapies in stroke patients that can further
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reduce the risk of vascular brain damage will remain
the best guarantee for decreasing the risk of cognitive
decline. Any progress in the management of all types of
CVD will be essential in this context.
Since the benefit of some specific pharmacologic
agents may vary depending on the distribution and
severity of cerebral damage, importance of brain and
cognitive reserve, but also on age, gender, metabolic or
genetic factors, new strategies that could better inte-
grate complex parameters at individual level should
be considered in future clinical trials for developing a
personalized approach to management.
The potential of various types of neuroprotective
agents for reducing cerebral tissue damage in CVD
needs further investigations. eHealth interventions for
improving prevention, clinical follow-up and treatment
will need specific studies. This approach might be also
used in the near future to enable innovative numeric reha-
bilitation and regular counselling via internet platforms.
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